Workshop explores racial PK differences, TDF-PI interaction.
Halima
Yasmin
Y
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D063065:Organophosphonates / Q000009:adverse effects / Q000493:pharmacokinetics*; D044469:Racial Groups; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics*; D000068698:Tenofovir
D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine